Heme oxygenase-1 (HO-1) confers protection to the vasculature and suppresses inflammatory properties of monocytes and macrophages. It is unclear how HO-1 determines the extent of vascular dysfunction in mice and humans.
Introduction
Heme oxygenase-1 (HO-1, encoded by the Hmox1 gene in mouse and HMOX1 gene in humans) exerts beneficial antioxidant and antiinflammatory effects, mainly by yielding the heme-breakdown products carbon monoxide (CO), biliverdin/bilirubin and stimulating expression of ferritin. Heme oxygenase-1 deficient cells are more susceptible to oxidative stress and cytotoxicity caused by heme and hydrogen peroxide. 1 Activation of HO-1 or administration of CO has been shown to provide protection from many-in particular vascular-pathologies. For instance, CO protected from restenosis and proliferative vascular disease in mouse models of vascular grafting and balloon injury. 2 Induction of HO-1 was shown to stimulate vascular relaxation via soluble guanylyl cyclase and cyclic guanosine monophosphate and prevented smooth muscle proliferation in vascular injury, 3 which was ascribed to CO bioactivity. High-fat diet fed Ldlr 2/ 2 mice transplanted with bone marrow from Hmox1
2/ 2
mice showed larger atherosclerotic lesions with greater macrophage content. Low density lipoprotein cholesterol-exposed macrophages isolated from HO-1 deficient mice secreted increased levels of interleukin-6 and monocyte chemoattractant protein-1 (MCP-1), 4 indicating that HO-1 activity and expression might determine the macrophage phenotype in cardiovascular disease (CVD). A pro-inflammatory phenotype of monocytes and macrophages has been proposed to be mechanistically important in the progression of atherosclerosis 5 as well as in some of the most relevant disease states that drive CVD such as arterial hypertension 6 and vascular dysfunction in diabetes mellitus. 7 Administration of heme induced HO-1 expression and prevented arterial hypertension in spontaneously hypertensive rats. 8 Heme oxygenase-1 is upregulated in response to angiotensin II (ATII) 9 as an endogenous mechanism to protect from ATII-induced nicotinamide dinucleotide phosphate (NADPH) oxidase activity, 10 and HO-1 induction has been shown to attenuate blood pressure increase in response to ATII. 11 Likewise, HO-1 induction protected from vasculopathy in streptozotocin (STZ) induced experimental diabetes in rats. 12 The (GT) n length polymorphism in the promoter region for the HMOX1 gene has been shown to influence HMOX1 gene expression before (short GT repeats: higher expression; longer GT repeats: lower expression). In selected patient populations, a correlation between the (GT) n repeat polymorphism in the HMOX1 gene promoter region and adverse cardiovascular phenotypes or outcomes has been assumed. 13, 14 It is incompletely understood, however, if HO-1 activity and expression correlates with endothelial function in humans or mice. Moreover, it is unknown whether the capacity of HO-1 to determine the phenotype of myelomonocytic cells impacts on endothelial function and potentially on patient outcomes. We therefore aimed to test the hypothesis that HO-1 expression and activity protects from vascular dysfunction and oxidative stress by guiding the polarization of monocytes and suppressing vascular inflammation.
Material and methods
The complete Materials and methods can be found in Supplementary material online. In brief, male Hmox1 +/+ , Hmox1 +/2 , and Hmox1 ). Animal treatment was granted by the Mainz University local Ethics Committee. Heme oxygenase activity in isolated mouse fibroblasts was measured by a calorimetric assay. In the mouse studies, we assessed blood pressure non-invasively by tail-cuff measurements, vascular endothelial inflammation by intravital microscopy, vascular function by isometric tension studies, vascular reactive oxygen species formation by oxidative fluorescent microtopography, protein expression by western blot, mRNA expression by quantitative real-time PCR, and vascular and circulating immune cell composition by flow cytometry. Five thousand individuals of the Gutenberg Health Study (GHS), a community-based, prospective, observational single-centre cohort study, were examined for flow-mediated dilation (FMD) and other parameters of vascular function, bilirubin levels, and (GT) n repeats in the promoter region of the HMOX1 gene by fragment analysis. Transcriptome-wide gene expression profiles in monocytes were assessed using Illumina HT-12 v3 BeadChips. The study protocol and sampling design were approved by the local ethics committee and by the local and federal data safety commissioners. In animal studies, data were expressed as mean + SD and statistically tested for significance by one-or two-way analyses of variance. Results of regression analyses are reported as betas with their 95% confidence intervals (CIs). All statistical analyses within GHS were performed using R version 2.14.2 software.
Results
Heme oxygenase-1 activity and expression preserve endothelial dysfunction and protect from vascular oxidative stress mice showed a stepwise and gradually impaired response to the endothelium-dependent vasodilator acetylcholine ( Figure 1B) . This direct link of HO-1 deficiency to endothelial dysfunction was not sufficiently counteracted by compensatory upregulation of HO-2 protein expression (Supplementary material online, Figure S1A ).
Stepwise increased ROS formation was abrogated by the flavindependent oxidoreductase inhibitor diphenyliodonium and significantly blunted by both the specific NADPH oxidase inhibitor Vas2870 and the protein kinase C inhibitor chelerythrine ( Figure 1C ). This implies an NADPH oxidase activation in HO-1 deficiency (see also Supplementary material online, Figure S1B ). Endothelial function and arterial hypertension in mice and humans endothelial dysfunction in mice that are prone to oxidant, metabolic, or inflammatory stress. 15 This regimen caused endothelial dysfunction in Hmox1 +/2 , while it did not significantly alter endothelial function in Hmox1 +/+ ( Figure 2 ). Additionally, STZ-induced diabetes mellitus and aging caused vascular endothelial dysfunction that was directly correlated with the HO-1 genotype in these mice and most pronounced, when the Hmox1 gene was completely absent (Supplementary material online, Figure S2A and B).
Monocytic HMOX1 mRNA expression is associated with endothelial function in humans with arterial hypertension
To study the relevance of HO-1 for vascular function in humans, we used the cross-sectional data in a study sample of n ¼ 5,000 individuals from the GHS, a primary prevention cohort study (Study sample A2, Supplementary material online, Table S1 ). We analysed the length of the HMOX1 promoter (GT) n repeat. In our cohort, we established a bimodal distribution of allele length frequency of 4937 individuals (Supplementary material online , Table S2 ), that matches well with the reported allele frequencies in other cohorts of individuals of Caucasian ethnicity 16 ( Figure 3A and B) . We then analysed, whether the (GT) n repeat length correlated with FMD in these individuals or with serum levels of bilirubin, a well-reported surrogate parameter of HO-1 bioactivity. As known from the literature and shown in our cohort, reproducibility of FMD under standardized conditions is good. 17, 18 As published before, FMD was significantly associated with sex, age, BMI, and hypertension. 17 However, HMOX1 promoter (GT) n repeats were neither correlated with bilirubin nor with FMD or other measures of vascular function, i.e. stiffness index being a measure for arterial stiffness and reflection index as a measure for vascular tone (Supplementary material online, Table S3 and Figure S3 ). We therefore decided to directly investigate HMOX1 mRNA expression levels in individuals from the GHS. Systematic transcriptomics analysis was performed in a subgroup of all GHS participants (n ¼ 1467) by mRNA array using mRNA isolated form venous blood monocytes as reported. 19 We found that monocytic HMOX1 mRNA expression had a Gaussian distribution in the GHS population ( Figure 3C ). When performing linear regression analysis, we found that monocytic HMOX1 mRNA expression levels were positively associated with FMD and with serum bilirubin levels in individuals with arterial hypertension ( Table 1) .
Heme oxygenase-1 expression determines the phenotype of monocytes and the extent and quality of vascular inflammation in arterial hypertension
Macrophages, inflammatory monocytes, and neutrophils are causally involved in the pathogenesis of arterial hypertension and vascular inflammation 6 and HO-1 has been shown to attenuate a pro-inflammatory response of macrophages 4, 20 in mouse models of atherosclerosis. We found that HMOX1 mRNA expression is firmly correlated with NOX2 mRNA expression in circulating monocytes (Supplementary material online, Figure S4 and Table  S5 ), supporting the concept that HO-1 is an endogenous protector from NADPH oxidase derived oxidative stress. 9, 10 Interestingly, monocytic mRNA expression of HMOX1 was inversely correlated with CD14, a marker of 'classical' (i.e. inflammatory) monocytes, in individuals with arterial hypertension ( Figure 3D and Table 2 ). We therefore again investigated Hmox1 +/ + , Hmox1 +/ 2 , and Hmox1 2/ 2 mice. Monocytic as well as aortic ( Figure 4A and B) mRNA levels of Ccr2 were drastically increased in Hmox1 2/ 2 when compared with Hmox1 +/+ mice. This CC-chemokine receptor binds MCP-1, the most important chemokine for monocyte chemotaxis, and is essential for vascular inflammatory remodeling in hypertension. Vascular inflammation in response to ATII was described to be absent when monocytes lack CCR2. 21 We thus in- Figure 4C) . In vascular homogenates, the number of CD45 + leukocytes was significantly increased in response to ATII in Hmox1 +/ 2 and Hmox1 2/2 mice; the blood count of these cells was essentially unchanged ( Figure 5A -B) . ATII induced vascular infiltration of CD11b + Ly6G + neutrophils that was significantly more pronounced in HO-1 deficient mice ( Figure 5C and D Figure S5) . Interestingly, the number of CD11b + Ly6C high inflammatory monocytes, the equivalent to CD14 high monocytes in humans, was drastically increased in the blood and to even greater extent in the aorta of ATII-infused mice that were fully deficient for Multivariable adjusted linear regression analysis of the association of HMOX1 mRNA expression with command variable FMD (a) and serum levels of bilirubin (b) in 1467 individuals of the GHS. Models were adjusted for sex, age, diabetes, smoking, arterial hypertension, dyslipidaemia, body mass index, family history of myocardial infarction and history of coronary artery disease, myocardial infarction, peripheral artery disease, chronic heart failure, stroke, atrial fibrillation, chronic kidney disease, chronic liver disease, chronic obstructive pulmonary disease and cancer, additionally for bilirubin (a) and FMD (b) and stratified into hypertensive (n ¼ 733) and normotensive (n ¼ 734) individuals. Significant P-values (P , 0.05) are highlighted in bold.
the Hmox1 gene ( Figure 5E and F ). This enhanced inflammatory phenotype was associated with increased ATII-induced arterial hypertension in Hmox1 deficient mice ( Figure 5G ).
Long (GT) n repeats are associated with arterial hypertension and increased all-cause mortality Association of (GT) n repeats and HO-1 expression differences have been primarily described in collectives with induced promoter activity 22 ; hypertension is consistently associated with FMD. 17 Based on our findings in animal models, we performed multiple logistic regression analyses and found that interaction of (GT) n repeat length in both alleles had an odds ratio . 1, implying a small but statistically significant adverse effect with regards to the prevalence of arterial hypertension (Supplementary material online, Table S6 ). Individuals with long (GT) n repeats (cutoff: 30/30) on both alleles had a more than two-fold increased risk for the prevalence of arterial hypertension (odds ratio: 2.166) compared with the protective reference short/short (GT) n repeats (i.e. ,23/23). Intriguingly, the cutoff of 30 on both alleles being the most frequent (GT) n repeat ( Figure 3A ) still was protective, whereas the risk of arterial hypertension drastically increased in individuals with very long (GT) n repeats on both alleles ( . ............ ............ ............ ............ ........... ............ ............ ............ ........... ............ ............ ............ ........... ............ . Regression analysis of the association of HMOX1 mRNA expression with CD14 (a, b) in 1467 individuals of the GHS. Two probes capture CD14 mRNA expression on Illumina HT12 BeadChips: ILMN_2396444 (a) and ILMN_1740015 (b), representing for total CD14 mRNA expression. The models were adjusted for sex, age, diabetes, smoking, arterial hypertension, dyslipidaemia, body mass index, family history of myocardial infarction and history of coronary artery disease, myocardial infarction, peripheral artery disease, chronic heart failure, stroke, atrial fibrillation, chronic kidney disease, chronic liver disease, chronic obstructive pulmonary disease and cancer and stratified into hypertensive (n ¼ 733) and normotensive (n ¼ 734). Significant P-values (P , 0.05) are highlighted in bold. cumulative survival. Individuals with long (GT) n repeats (cutoff: 30/30 on both alleles) had higher all-cause mortality compared with carriers of short (GT) n repeats (cutoff: 23/23 on both alleles; Figure 6 ).
Discussion
Here, we present evidence that HO-1 activity and expression correlate with improved endothelial function and attenuated Figure 7 ). Our data strengthen the concept that HO-1 may counteract NADPH oxidase activity and expression (especially in phagocytic cells) by controlling and reducing the pool of available heme necessary for proper gp91 phox (Nox2) biosynthesis and function. 23 Consequently, HO-1 deficient mice were more susceptible to vascular injury induced by ATII, hyperglycaemia and aging that cannot be compensated by HO-2. In western blot analysis of aortic tissue, we found evidence for an increase of eNOS activity, presumably to compensate for lack of endogenous CO, the sGC-activating breakdown product of heme (Supplementary material online, Figure  S1C ). However, these counterregulatory changes are obviously not sufficient to prevent the development of endothelial dysfunction in mice deficient in HO-1. Increased monocytic HMOX1 mRNA expression was associated with reduced markers of inflammatory polarization of monocytes and higher serum bilirubin levels. The inverse and highly significant correlation with monocytic CD14mRNA expression (marking inflammatory polarization of monocytes) was evident in all individuals, whereas there was a positive correlation with endothelial function only in humans with hypertension. These observations strongly suggest, that hypertensive individuals with lower HO-1 These cells can develop independently of bone marrow-derived cells. 32 Heme oxygenase-1 deficiency did not have a major impact on the levels of vascular F4/80 + macrophages; these findings points towards the multifaceted and divergent roles of inflammation in different disease states and highlight the impact of different myeloid cell lineages for CVD. HMOX1 expression on monocytes was strongly associated with both FMD and markers of vascular inflammation in our study. It was recently shown that GT (n) repeats . 30 on both alleles (L/L genotype) are associated with higher incidence of CVD and progressive atherosclerosis in a population-based cohort of 812 individuals. 33 Interestingly, we have found, that this unfavourable HMOX1 gene promoter length polymorphism potentially increases the risk of arterial hypertension (Table 3 ) and is associated with increased all-cause mortality ( Figure 6 ). Current guidelines on the management of arterial hypertension put little emphasis on the use of biomarkers for risk stratification. 34 Therefore, development of clinically applicable assays to routinely assess HO-1 expression or activity or HMOX1 gene promoter polymorphisms in circulating cells might result in useful biomarkers. Future studies are needed to test whether such an approach would improve risk stratification for primary or secondary prevention of CVD events, in particular in patients with arterial hypertension.
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